1
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Bae HJ, Chang YG, Noh JH, Kim JK, Eun JW,
Jung KH, Kim MG, Shen Q, Ahn YM, Kwon SH, et al: DBC1 does not
function as a negative regulator of SIRT1 in liver cancer. Oncol
Lett. 4:873–877. 2012.PubMed/NCBI
|
3
|
Dimauro T and David G: Ras-induced
senescence and its physiological relevance in cancer. Curr Cancer
Drug Targets. 10:869–876. 2010. View Article : Google Scholar : PubMed/NCBI
|
4
|
Serrano M, Lin AW, McCurrach ME, Beach D
and Lowe SW: Oncogenic ras provokes premature cell senescence
associated with accumulation of p53 and p16INK4a. Cell. 88:593–602.
1997. View Article : Google Scholar : PubMed/NCBI
|
5
|
Braig M, Lee S, Loddenkemper C, Rudolph C,
Peters AH, Schlegelberger B, Stein H, Dörken B, Jenuwein T and
Schmitt CA: Oncogene-induced senescence as an initial barrier in
lymphoma development. Nature. 436:660–665. 2005. View Article : Google Scholar : PubMed/NCBI
|
6
|
Ferbeyre G: Barriers to Ras
transformation. Nat Cell Biol. 9:483–485. 2007. View Article : Google Scholar : PubMed/NCBI
|
7
|
New L, Jiang Y and Han J: Regulation of
PRAK subcellular location by p38 MAP kinases. Mol Biol Cell.
14:2603–2616. 2003. View Article : Google Scholar : PubMed/NCBI
|
8
|
Sun P, Yoshizuka N, New L, Moser BA, Li Y,
Liao R, Xie C, Chen J, Deng Q, Yamout M, et al: PRAK is essential
for ras-induced senescence and tumor suppression. Cell.
128:295–308. 2007. View Article : Google Scholar : PubMed/NCBI
|
9
|
Yamagata K, Sanders LK, Kaufmann WE, Yee
W, Barnes CA, Nathans D and Worley PF: Rheb, a growth factor- and
synaptic activity-regulated gene, encodes a novel Ras-related
protein. J Biol Chem. 269:16333–16339. 1994.PubMed/NCBI
|
10
|
Inoki K, Li Y, Xu T and Guan KL: Rheb
GTPase is a direct target of TSC2 GAP activity and regulates mTOR
signaling. Genes Dev. 17:1829–1834. 2003. View Article : Google Scholar : PubMed/NCBI
|
11
|
Babcock JT and Quilliam LA: Rheb/mTOR
activation and regulation in cancer: Novel treatment strategies
beyond rapamycin. Curr Drug Targets. 12:1223–1231. 2011. View Article : Google Scholar : PubMed/NCBI
|
12
|
Wazir U, Newbold RF, Jiang WG, Sharma AK
and Mokbel K: Prognostic and therapeutic implications of mTORC1 and
Rictor expression in human breast cancer. Oncol Rep. 29:1969–1974.
2013.PubMed/NCBI
|
13
|
Lu ZH, Shvartsman MB, Lee AY, Shao JM,
Murray MM, Kladney RD, Fan D, Krajewski S, Chiang GG, Mills GB, et
al: Mammalian target of rapamycin activator RHEB is frequently
overexpressed in human carcinomas and is critical and sufficient
for skin epithelial carcinogenesis. Cancer Res. 70:3287–3298. 2010.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Zheng H, Liu A, Liu B, Li M, Yu H and Luo
X: Ras homologue enriched in brain is a critical target of
farnesyltransferase inhibitors in non-small cell lung cancer cells.
Cancer Lett. 297:117–125. 2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Zheng M, Wang YH, Wu XN, Wu SQ, Lu BJ,
Dong MQ, Zhang H, Sun P, Lin SC, Guan KL, et al: Inactivation of
Rheb by PRAK-mediated phosphorylation is essential for
energy-depletion-induced suppression of mTORC1. Nat Cell Biol.
13:263–272. 2011. View
Article : Google Scholar : PubMed/NCBI
|
16
|
Llovet JM, Di Bisceglie AM, Bruix J,
Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M,
Talwalkar J and Gores GJ: Panel of Experts in HCC-Design Clinical
Trials: Design and endpoints of clinical trials in hepatocellular
carcinoma. J Natl Cancer Inst. 100:698–711. 2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Edmondson HA and Steiner PE: Primary
carcinoma of the liver: A study of 100 cases among 48,900
necropsies. Cancer. 7:462–503. 1954. View Article : Google Scholar : PubMed/NCBI
|
18
|
Kononen J, Bubendorf L, Kallioniemi A,
Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G
and Kallioniemi OP: Tissue microarrays for high-throughput
molecular profiling of tumor specimens. Nat Med. 4:844–847. 1998.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Shengbing Z, Feng LJ, Bin W, Lingyun G and
Aimin H: Expression of KiSS-1 gene and its role in invasion and
metastasis of human hepatocellular carcinoma. Anat Rec (Hoboken).
292:1128–1134. 2009. View
Article : Google Scholar : PubMed/NCBI
|
20
|
Eom M, Han A, Lee MJ and Park KH:
Expressional difference of RHEB, HDAC1, and WEE1 proteins in the
stromal tumors of the breast and their significance in
tumorigenesis. Korean J Pathol. 46:324–330. 2012. View Article : Google Scholar : PubMed/NCBI
|
21
|
Kobayashi T, Shimizu Y, Terada N, Yamasaki
T, Nakamura E, Toda Y, Nishiyama H, Kamoto T, Ogawa O and Inoue T:
Regulation of androgen receptor transactivity and mTOR-S6 kinase
pathway by Rheb in prostate cancer cell proliferation. Prostate.
70:866–874. 2010.PubMed/NCBI
|
22
|
Prieur A and Peeper DS: Cellular
senescence in vivo: A barrier to tumorigenesis. Curr Opin Cell
Biol. 20:150–155. 2008. View Article : Google Scholar : PubMed/NCBI
|
23
|
Menendez JA and Alarcón T: Metabostemness:
a new cancer hallmark. Front Oncol. 4:2622014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
25
|
Aksamitiene E, Kiyatkin A and Kholodenko
BN: Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt
pathways: A fine balance. Biochem Soc Trans. 40:139–146. 2012.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Nardella C, Chen Z, Salmena L, Carracedo
A, Alimonti A, Egia A, Carver B, Gerald W, Cordon-Cardo C and
Pandolfi PP: Aberrant Rheb-mediated mTORC1 activation and Pten
haploinsufficiency are cooperative oncogenic events. Genes Dev.
22:2172–2177. 2008. View Article : Google Scholar : PubMed/NCBI
|
27
|
Mavrakis KJ, Zhu H, Silva RL, Mills JR,
Teruya-Feldstein J, Lowe SW, Tam W, Pelletier J and Wendel HG:
Tumorigenic activity and therapeutic inhibition of Rheb GTPase.
Genes Dev. 22:2178–2188. 2008. View Article : Google Scholar : PubMed/NCBI
|